DARA signs commercialization agreement with Uman Pharma for anticancer agent
Gemcitabine is indicated for first-line therapy for ovarian, breast, lung, and pancreatic cancers. Uman is expected to file an abbreviated new drug application (ANDA) for gemcitabine with the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.